Immune cell clues in breast cancer tumors may predict Long-Term survival
NCT ID NCT07545434
First seen Apr 25, 2026 · Last updated Jun 23, 2026 · Updated 12 times
Summary
This study examined tumor samples from 3,646 women with early-stage breast cancer who had already received chemotherapy after surgery. Researchers measured specific immune cells (tumor-infiltrating lymphocytes and CD8+ T cells) to see if their presence was linked to how long patients lived without their cancer returning. The goal was to better understand the role of the immune system in fighting breast cancer and potentially improve risk prediction.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EARLY BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Hellenic Cooperative Oncology Group
Athens, 11526, Greece
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this analysis could help doctors better predict which early breast cancer patients are at higher risk of recurrence, guiding more personalized treatment decisions.
What could go wrong
This is an observational analysis of existing data, not a test of a new treatment. The findings may not change current practice without further validation in prospective studies.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.